[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 4 sources · 7 days · First seen · Last updated

ARPA-H BioStabilization Systems program

Overview

The Advanced Research Projects Agency for Health (ARPA-H) has launched the BioStabilization Systems (BoSS) program, committing up to $87 million over four years. The initiative focuses on developing technologies for the production, storage, and transport of cell-based biologic medicines at room temperature to reduce reliance on expensive cold-chain logistics.

As part of the Phase I funding round, the Reversible Ambient Biostabilization (RAB) team, led by Likarda and managed by Draper, was awarded up to $7.3 million. The multidisciplinary team includes CaseBioscience, CPSI Biotech, Fresenius Kabi, MiNK Therapeutics, and the University of Colorado Boulder. The RAB team intends to use AI-assisted design and freeze-assisted droplet drying to optimize cell stability, aiming to make biological medicines as easy to ship and store as aspirin.

Entities

Likarda · Advanced Research Projects Agency for Health · Department of Health and Human Services · University of Colorado Boulder · ARPA-H

Timeline

  1. [HEALTH] 2 sources
    ARPA-H funds program to stabilize cell therapies at room temperature

    ARPA-H is investing up to $87 million into its BoSS program to develop room-temperature storage and transport solutions for cell-based therapies and biologics.

  2. [TECHNOLOGY] 2 sources
    ARPA-H awards $7.3 million to team including CaseBioscience

    CaseBioscience joined a Likarda-led team awarded $7.3 million by ARPA-H to develop room-temperature storage and transport methods for cell therapies, aiming to reduce cold-chain logistics dependency.

Sources

ad-hoc-news.de · cagliarilivemagazine.it · genengnews.com · research.njit.edu